Learn how VHHs can revolutionize CAR-T cell therapy
Small, stable and robust, VHHs offer an attractive construct for use as targeting agents in cell therapies.
Explore the benefits of VHHs in CAR-T cell therapy and learn how this innovative approach can enhance the effectiveness of next-generation cancer treatments.
Advantages of
VHH in Cell Therapy
Smaller constructs mean more space for multi-specific targeting modules or next-generation signalling domains.
References:
1. Jayaraman J et al. (2020) Ebiomedicine 58: 102931
2. Lamers CH, et al. (2011) Blood 117(1):72-82
3. Ackaert C et al. (2021) Front. Immunol. 12: 632687
4. Desmyter A et al. (1996) Nat Struct Biol 3(9): 803-811
Isogenica’s
VHH in CAR-T Resources
Protein & Antibody Engineering Summit VHH as Building Blocks for Immune and Tumour
In this webcast, speakers will introduce the unique benefits of the VHH antibodies generated from the LlamdA™ synthetic library and summarize how VHHs can be engineered to tune their binding selectivity and specificity and help optimize the next generation of cell therapies.
“Small modalities, deep impact”: VHH antibodies as complementary approaches for challenging therapeutic targets
In this webcast, speakers will introduce the unique benefits of the VHH antibodies generated from the LlamdA™ synthetic library and summarize how VHHs can be engineered to tune their binding selectivity and specificity and help optimize the next generation of cell therapies.
From monoclonals to bi-specifics: Harnessing the transformative power of VHHs to supercharge IgG therapeutics
We explain how VHHs – small format single-domain antibody fragments – have a range of unique properties that make them ideal for enhancing the therapeutic potential of conventional IgG antibodies.
Partnerships at Isogenica
Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including one clinical Phase II asset and eleven partnered pre-clinical and discovery programs.